TotalMarketCap

Valneva SE

VALNNasdaq FranceHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$532.935 M

$5.62 -0.24%

Close of 6 Nov 2026

As of 6 Nov 2026, Valneva SE (VALN) has a market capitalization of $532.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

173,539,745

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #60DBV TechnologiesDBVT$614.9M
  2. #61Iambic TherapeuticsIAM$550.1M
  3. #62Valneva SEVALN$532.9M
  4. #63Entera BioENTX$521.8M
  5. #64SurrozenSRZN$517.4M

What if Valneva SE were worth as much as…

Open the what-if tool →

Gold $28.2T

$297,588.55

Per share 52,984× higher

Bitcoin $1.53T

$16,102.00

Per share 2,867× higher

Apple $5.02T

$52,861.36

Per share 9,412× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Valneva SE are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.